Article

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

Division of Hematology, Department of Medicine, The Ohio State University, Columbus 43210, USA.
Blood (Impact Factor: 10.43). 06/2012; 120(9):1765-73. DOI: 10.1182/blood-2012-04-423160
Source: PubMed

ABSTRACT Chromosome maintenance protein 1 (CRM1) is a nuclear export receptor involved in the active transport of tumor suppressors (e.g., p53 and nucleophosmin) whose function is altered in cancer because of increased expression and overactive transport. Blocking CRM1-mediated nuclear export of such proteins is a novel therapeutic strategy to restore tumor suppressor function. Orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of this protein have been recently developed. Here we investigated the antileukemic activity of KPT-SINE (KPT-185 and KPT-276) in vitro and in vivo in acute myeloid leukemia (AML). KPT-185 displayed potent antiproliferative properties at submicromolar concentrations (IC50 values; 100-500 nM), induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines and patient blasts. A strong down-regulation of the oncogene FLT3 after KPT treatment in both FLT3-ITD and wild-type cell lines was observed. Finally, using the FLT3-ITD-positive MV4-11 xenograft murine model, we show that treatment of mice with oral KPT-276 (analog of KPT-185 for in vivo studies) significantly prolongs survival of leukemic mice (P < .01). In summary, KPT-SINE are highly potent in vitro and in vivo in AML. The preclinical results reported here support clinical trials of KPT-SINE in AML.

0 Followers
 · 
199 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study of the detailed molecular history of cancer development is one of the most promising techniques to understand and fight this diverse and prevalent disease. Unfortunately, this history is as diverse as cancer itself. Therefore, even with next-generation sequencing techniques, it is not easy to distinguish significant (driver) from random (passenger) events. The International Cancer Genome Consortium (ICGC) was formed to solve this fundamental issue by coordinating the sequencing of samples from 50 different cancer types and/or sub-types that are of clinical and societal importance. The contribution of Spain in this consortium has been focused on chronic lymphocytic leukemia (CLL). This approach has unveiled new and unexpected events in the development of CLL. In this review, we introduce the approaches utilized by the consortium for the study of the CLL genome and discuss the recent results and future perspectives of this work.
    Clinical and Translational Oncology 08/2012; 15(1). DOI:10.1007/s12094-012-0922-z · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this issue of Blood, Ranganathan et al seek a holy grail: evidence that a drug with a novel mechanism of action may be effective for acute myeloid leukemia patients.(1)
    Blood 08/2012; 120(9):1759-60. DOI:10.1182/blood-2012-07-439166 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of combination chemotherapy to cure acute lymphoblastic leukemia in children and acute myeloid leukemia in adults emerged for acute myeloid leukemia in the 1960s and for acute lymphoblastic leukemia in the 1980s as a paradigm for curing any disseminated cancer. This article summarizes recent developments and considerations in the use of acute leukemia xenografts established in immunodeficient mice to elucidate the genetic and genomic basis of acute leukemia pathogenesis and treatment response.
    Pharmacogenomics 11/2012; 13(15):1759-72. DOI:10.2217/pgs.12.158 · 3.43 Impact Factor